Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 41
Filter
1.
Hematology Am Soc Hematol Educ Program ; 2016(1): 598-604, 2016 Dec 02.
Article in English | MEDLINE | ID: mdl-27913534

ABSTRACT

Myelodysplastic syndrome (MDS) and myeloproliferative disorders are rare in children; they are divided into low-grade MDS (refractory cytopenia of childhood [RCC]), advanced MDS (refractory anemia with excess blasts in transformation), and juvenile myelomonocytic leukemia (JMML), each with different characteristics and management strategies. Underlying genetic predisposition is recognized in an increasing number of patients. Germ line GATA2 mutation is found in 70% of adolescents with MDS and monosomy 7. It is challenging to distinguish RCC from aplastic anemia, inherited bone marrow failure, and reactive conditions. RCC is often hypoplastic and may respond to immunosuppressive therapy. In case of immunosuppressive therapy failure, hypercellular RCC, or RCC with monosomy 7, hematopoietic stem cell transplantation (HSCT) using reduced-intensity conditioning regimens is indicated. Almost all patients with refractory anemia with excess blasts are candidates for HSCT; children age 12 years or older have a higher risk of treatment-related death, and the conditioning regimens should be adjusted accordingly. Unraveling the genetics of JMML has demonstrated that JMML in patients with germ line PTPN11 and CBL mutations often regresses spontaneously, and therapy is seldom indicated. Conversely, patients with JMML and neurofibromatosis type 1, somatic PTPN11, KRAS, and most of those with NRAS mutations have a rapidly progressive disease, and early HSCT is indicated. The risk of relapse after HSCT is high, and prophylaxis for graft-versus-host disease and monitoring should be adapted to this risk.


Subject(s)
Anemia, Aplastic , Anemia, Refractory, with Excess of Blasts , Leukemia, Myelomonocytic, Juvenile , Adolescent , Anemia, Aplastic/diagnosis , Anemia, Aplastic/genetics , Anemia, Aplastic/immunology , Anemia, Aplastic/therapy , Anemia, Refractory, with Excess of Blasts/diagnosis , Anemia, Refractory, with Excess of Blasts/genetics , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/therapy , Child , Child, Preschool , Chromosome Deletion , Chromosomes, Human, Pair 7/genetics , Chromosomes, Human, Pair 7/immunology , Female , GATA2 Transcription Factor/genetics , GATA2 Transcription Factor/immunology , GTP Phosphohydrolases/genetics , GTP Phosphohydrolases/immunology , Humans , Immunosuppression Therapy/methods , Infant , Leukemia, Myelomonocytic, Juvenile/diagnosis , Leukemia, Myelomonocytic, Juvenile/genetics , Leukemia, Myelomonocytic, Juvenile/immunology , Leukemia, Myelomonocytic, Juvenile/therapy , Male , Membrane Proteins/genetics , Membrane Proteins/immunology , Protein Tyrosine Phosphatase, Non-Receptor Type 11/genetics , Protein Tyrosine Phosphatase, Non-Receptor Type 11/immunology , Proto-Oncogene Proteins c-cbl/genetics , Proto-Oncogene Proteins c-cbl/immunology , Proto-Oncogene Proteins p21(ras)/genetics , Proto-Oncogene Proteins p21(ras)/immunology
2.
Cancer Immunol Res ; 4(6): 474-480, 2016 06.
Article in English | MEDLINE | ID: mdl-26966176

ABSTRACT

Antibodies aimed at blocking the interaction between programmed cell death-1 (PD-1) and its ligands have shown impressive efficacy in a variety of malignancies and are generally well tolerated. Research has focused intensely on T cells and their interaction with cells within melanoma tumors, while relatively little is understood about the systems immunology of the cells in the blood during checkpoint inhibitor therapy. Longitudinal cytomic analysis using mass cytometry can characterize all the cells in a small sample of blood and has the potential to reveal key shifts in the cellular milieu occurring during treatment. We report a case of advanced melanoma in which mass cytometry detected abnormal myeloid cells resulting from myelodysplastic syndrome (MDS) in the blood following treatment with an anti-PD-1 agent. Myeloid blasts comprised <1% of peripheral blood mononuclear cells (PBMC) 1 month after the start of treatment. Six months after starting therapy, myeloid blasts comprised 5% of PBMCs, and a bone marrow biopsy confirmed refractory anemia with excess blasts-2 (RAEB-2). Longitudinal mass cytometry immunophenotyping comprehensively characterized blast phenotype evolution and revealed elevated PD-1 expression on the surface of nonblast myeloid cells. These findings highlight the clinical significance of cytomic monitoring, indicate that the myeloid compartment should be monitored during checkpoint inhibitor therapy, and emphasize the value of systems immunology in medicine. Cancer Immunol Res; 4(6); 474-80. ©2016 AACR.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Antineoplastic Agents/adverse effects , Melanoma/drug therapy , Myelodysplastic Syndromes/chemically induced , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Aged , Anemia, Refractory, with Excess of Blasts/chemically induced , Anemia, Refractory, with Excess of Blasts/diagnosis , Anemia, Refractory, with Excess of Blasts/immunology , Antibodies, Monoclonal, Humanized/pharmacology , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Disease Progression , Female , Flow Cytometry/methods , Follow-Up Studies , Humans , Immunophenotyping , Melanoma/immunology , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/immunology , Programmed Cell Death 1 Receptor/metabolism
3.
Histopathology ; 61(2): 200-11, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22690734

ABSTRACT

AIMS: There is increasing evidence that autoimmunity is involved in the pathogenesis of myelodysplastic syndromes (MDS). We examined the number of apoptotic cells, and analysed the T cells and the T cell receptor gene rearrangements in bone marrow trephines of patients with low-grade MDS [refractory anaemia (RA), refractory anaemia with ringed sideroblasts (RAS) and refractory cytopenia with multilineage dysplasia (RCMD)] to investigate the correlation between T cells and apoptosis. METHODS AND RESULTS: Bone marrow trephines from 30 patients with RA, seven patients with RCMD, four patients with RAS and 11 normal bone marrow donors were stained for CD3 and for apoptotic cells using immunohistochemistry and terminal deoxynucleotidyl transferase 2'-deoxyuridine, 5'-triphosphate (dUTP) nick end labelling (TUNEL) technique, respectively. The positive cells were quantified by computer-assisted image analysis. In addition, CD 8 and T cell-restricted intracellular antigen-1 (TIA-1)-positive cells were analysed by single staining and evaluated semiquantitatively by light microscopy. Junctional diversity of the T cell receptor (TCR) α-, ß- and γ-chains were analysed in 24 cases of RA and RCMD by reverse transcription-polymerase chain reaction (RT-PCR). In all cases of RA, RCMD and RAS an increase of apoptotic cells was accompanied by an increase of T cells, when compared to normal donors (P < 0.001). Expression of TIA-1 was found in 33 of 41 patients with low-grade MDS. In contrast, normal controls showed either no or only very weak expression. Furthermore, 14 of 24 cases with low-grade MDS showed clonal TCR gene rearrangement. CONCLUSION: These findings provide evidence that increased apoptosis in low-grade MDS correlates with increased numbers of cytotoxic T cells. A considerable proportion of the MDS cases showed clonal TCR rearrangement suggesting an antigen-driven selection of the T cells. We therefore speculate that cases of MDS can be accompanied by a presumably autoreactive T cell-mediated apoptosis induction in bone marrow cells.


Subject(s)
Apoptosis/immunology , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/pathology , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/pathology , Adult , Aged , Aged, 80 and over , Anemia, Refractory/genetics , Anemia, Refractory/immunology , Anemia, Refractory/pathology , Anemia, Refractory, with Excess of Blasts/genetics , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/pathology , Autoimmunity , Base Sequence , Bone Marrow Cells/immunology , Bone Marrow Cells/pathology , Case-Control Studies , DNA Primers/genetics , Female , Gene Rearrangement, T-Lymphocyte , Humans , Immunophenotyping , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Myelodysplastic Syndromes/genetics , Reverse Transcriptase Polymerase Chain Reaction
4.
Blood ; 113(26): 6541-8, 2009 Jun 25.
Article in English | MEDLINE | ID: mdl-19389880

ABSTRACT

This study investigated the immunogenicity of Wilms tumor gene product 1 (WT1)-peptide vaccination in WT1-expressing acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients without curative treatment option. Vaccination consisted of granulocyte-macrophage colony-stimulating factor subcutaneously days 1 to 4, and WT1.126-134 peptide and 1 mg keyhole limpet hemocyanin on day 3. The initial 9 patients received 4 vaccinations biweekly, then monthly, and the subsequent 10 patients received continual biweekly vaccination. Seventeen AML patients and 2 refractory anemia with excess blasts patients received a median of 11 vaccinations. Treatment was well tolerated. Objective responses in AML patients were 10 stable diseases (SDs) including 4 SDs with more than 50% blast reduction and 2 with hematologic improvement. An additional 4 patients had clinical benefit after initial progression, including 1 complete remission and 3 SDs. WT1 mRNA levels decreased at least 3-fold from baseline in 35% of patients. In 8 of 18 patients, WT1-tetramer(+) T cells increased in blood and in 8 of 17 patients in bone marrow, with a median frequency in bone marrow of 0.18% at baseline and 0.41% in week 18. This WT1 vaccination study provides immunologic, molecular, and preliminary evidence of potential clinical efficacy in AML patients, warranting further investigations.


Subject(s)
Anemia, Refractory, with Excess of Blasts/therapy , Cancer Vaccines/therapeutic use , Immunotherapy, Active , Leukemia, Myeloid/therapy , Peptide Fragments/immunology , WT1 Proteins/immunology , Acute Disease , Adjuvants, Immunologic/administration & dosage , Aged , Aged, 80 and over , Anemia, Refractory, with Excess of Blasts/genetics , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/metabolism , CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/immunology , Erythema/etiology , Female , Genes, Wilms Tumor , Humans , Immunization Schedule , Immunotherapy, Active/adverse effects , Injections, Intradermal , Injections, Subcutaneous , Leukemia, Myeloid/genetics , Leukemia, Myeloid/immunology , Leukemia, Myeloid/metabolism , Male , Middle Aged , Neoplasm Proteins/immunology , Peptide Fragments/administration & dosage , Peptide Fragments/adverse effects , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Salvage Therapy , T-Cell Antigen Receptor Specificity , WT1 Proteins/administration & dosage , WT1 Proteins/adverse effects
5.
Exp Hematol ; 37(3): 386-94, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19136196

ABSTRACT

OBJECTIVE: The capacity of mononuclear blood cells to form autoreactive cytotoxic T lymphocytes was investigated in order to elucidate the mechanism of successful immunosuppressive therapy in some myelodysplastic syndrome (MDS) patients (autoreactivity studies). The failure in autoreactivity studies raised the question of alloreactive cytotoxic T lymphocyte formation in MDS (alloreactivity studies). MATERIALS AND METHODS: Sixteen MDS patients and relevant controls were examined. Autoreactive lymphocytes directed against autologous bone marrow mononuclear cells and alloreactive lymphocytes directed against unrelated third-party cells were tested using cytotoxicity assay. In addition, we used one-way mixed lymphocyte reaction, human androgen receptor test for clonality detection, and enzyme-linked immunosorbent assay kits for tumor necrosis factor and interferon-gamma testing. RESULTS: We did not confirm the presence of autoreactive T cells in eight of nine MDS patients tested. The response to allogeneic cells was impaired in 11 of 16 MDS patients, more often in refractory anemia (RA; 80%) than in RA with ring sideroblasts (40%). Interestingly, the response to allogeneic cells in mixed lymphocyte reaction was normal in all MDS patients. T lymphocytes were polyclonal in all but one patient. Tumor necrosis factor and interferon-gamma level in supernatants of mononuclear cells was significantly reduced in RA. CONCLUSION: The presumed autoaggressive T cells were not confirmed in MDS in our experimental arrangement. Alloreactivity studies demonstrated the impairment of effector cytotoxic phase of cell-mediated immunological reaction in MDS, namely in RA. The significance of our finding of defective cytotoxicity for pathogenesis, clinical course, and even for therapy is discussed together with other immunological defects reported so far.


Subject(s)
Autoimmunity , Myelodysplastic Syndromes/immunology , T-Lymphocytes, Cytotoxic/immunology , Anemia, Refractory/immunology , Anemia, Refractory, with Excess of Blasts/immunology , Case-Control Studies , Clone Cells , Humans , Immunity , Leukocytes/pathology , Myelodysplastic Syndromes/pathology
6.
Ann Hematol ; 87(4): 257-62, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18158579

ABSTRACT

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by absence of CD55 and CD59 from the surface of affected cells. PNH has been associated with myelodysplastic syndromes (MDS). The aim of our study was to estimate the prevalence of the PNH clone in MDS patients by detecting CD55 and CD59 deficiency. We studied 90 MDS patients: 19 patients with RA, 15 with refractory anemia with ringed sideroblasts (RARS), 18 with refractory anemia with excess of blasts (RAEB), 17 with refractory anemia with excess of blasts in transformation (RAEB-t), and 21 with chronic myelomonocytic leukemia (CMML). Twenty healthy individuals were also studied as the control group. We studied the PNH clone on granulocytes of these patients with the aid of flow cytometry. CD55- and CD59-deficient granulocytic populations were detected in 15.5% of MDS patients compared to 2.8% of normal individuals. Among the subgroups of the study, significant difference was present in three cases: (1) between CMML and control, (2) between CMML and RA, and (3) between CMML and RARS. These data indicate a possible association between PNH phenotype and MDS. MDS patients of worse prognosis (CMML) express more strongly the PNH clone compared to those of better prognosis (RA and RARS). Perhaps, the examination of MDS patients for the PNH clone by flow cytometry could provide us with a valuable prognostic tool.


Subject(s)
Anemia, Refractory, with Excess of Blasts/blood , CD55 Antigens/blood , CD59 Antigens/blood , Granulocytes/immunology , Hemoglobinuria, Paroxysmal/blood , Myelodysplastic Syndromes/blood , Analysis of Variance , Anemia, Refractory, with Excess of Blasts/immunology , Antigens, CD/genetics , CD55 Antigens/analysis , CD59 Antigens/analysis , Female , Hemoglobinuria, Paroxysmal/immunology , Humans , Male , Myelodysplastic Syndromes/immunology
7.
Acta Haematol ; 105(1): 1-6, 2001.
Article in English | MEDLINE | ID: mdl-11340246

ABSTRACT

BACKGROUND: Few immunohematological studies have been done in myelodysplastic syndrome (MDS). METHODS: Twenty-nine MDS patients were retrospectively evaluated with a direct antiglobulin test (DAT), antibody screening, serum electrophoresis and immunoelectrophoresis. Clinical and laboratory studies (hemoglobin level, reticulocyte count, DHL, total and indirect bilirubin) were done simultaneously, as well as the French-American-British subtype and bone marrow biopsy findings. RESULTS: Alloantibodies were demonstrated in 17 patients (58.6%), autoantibodies in 10 (34.4%) patients and cold agglutinin in 18 (62%) patients. DAT was mediated by only IgG in 8 patients (80%), by IgG and C3 in 1 patient (10%) and by IgG, IgA and C3 in 1 (10%) patient. No hemolytic disease occurred in patients with autoantibodies. Increased serum gammaglobulin was observed in 16 (54.4%) patients. There was no correlation between the incidence of allo-/autoantibodies and the gammaglobulin level (p = 0.937) and the presence of lymphocyte infiltrates in bone marrow biopsies (p = 0.156). No significant difference was observed when the incidence of autoantibodies and number of red blood cell transfusions were compared (p = 0.334). Patients with refractory anemia and refractory anemia with ringed sideroblasts subtypes had a higher incidence of allo-/autoantibodies than other MDS subtypes (p = 0.03). CONCLUSION: Patients with MDS, in particular refractory anemia and refractory anemia with ringed sideroblasts have a high incidence of allo- and autoantibodies, probably related to intrinsic immune disorder, without clinical or laboratory hemolysis.


Subject(s)
Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/immunology , Adult , Aged , Aged, 80 and over , Agglutinins/blood , Anemia, Refractory/immunology , Anemia, Refractory, with Excess of Blasts/immunology , Autoantibodies/blood , Biopsy , Bone Marrow/pathology , Complement C3/analysis , Coombs Test , Cryoglobulins , Erythrocyte Transfusion , Female , Humans , Immunoelectrophoresis , Immunoglobulin A/blood , Immunoglobulin G/blood , Isoantibodies/blood , Lymphocytes/pathology , Male , Middle Aged , Myelodysplastic Syndromes/pathology , Retrospective Studies
8.
Br J Haematol ; 112(1): 195-200, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11167802

ABSTRACT

Myelodysplastic syndrome (MDS) and T-cell large granular lymphocytic disease (T-LGL) are bone marrow failure disorders. Successful use of immunosuppressive agents to treat cytopenia in MDS and LGL suggests a common pathophysiology for the two conditions. Of 100 patients with initial diagnoses of either MDS or T-LGL referred to the National Institutes of Health for immunosuppressive treatment of cytopenia, nine had characteristics of both T-LGL and MDS (T-LGL/MDS). Fifteen patients with T-LGL received cyclosporin (CSA) (10 responses). Eight out of nine patients with T-LGL/MDS received CSA (two responses) and one patient received ATG (one response). Of 76 patients with MDS, eight received CSA (one response) and 68 received ATG (21 responses). The response to immunosuppression was significantly lower in patients with T-LGL/MDS and MDS than in patients with T-LGL disease alone (28% vs. 66%, P = 0.01). The proportion of T-helper cells and T-suppressor cells with an activated phenotype (HLA-DR(+)) was increased in patients with T-LGL, T-LGL/MDS and MDS, but the increase in activated T-suppressor cells in patients with T-LGL/MDS was not statistically significant. Autoreactive T cells may suppress haematopoiesis and contribute to the cytopenia in T-LGL and some patients with MDS, leading to T-LGL/MDS. The lower response rate of MDS or T-LGL/MDS to immunosuppression, compared with T-LGL alone, may reflect the older age and intrinsic stem cell abnormalities in MDS and T-LGL/MDS patients.


Subject(s)
Leukemia, T-Cell/complications , Myelodysplastic Syndromes/complications , Adult , Age Factors , Aged , Anemia, Refractory/complications , Anemia, Refractory/genetics , Anemia, Refractory/immunology , Anemia, Refractory, with Excess of Blasts/complications , Anemia, Refractory, with Excess of Blasts/genetics , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Sideroblastic/complications , Anemia, Sideroblastic/genetics , Anemia, Sideroblastic/immunology , Female , Gene Rearrangement, T-Lymphocyte , Humans , Immunophenotyping , Karyotyping , Leukemia, T-Cell/genetics , Leukemia, T-Cell/immunology , Lymphocyte Count , Male , Middle Aged , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/immunology , T-Lymphocytes, Helper-Inducer/immunology , T-Lymphocytes, Regulatory/immunology
9.
Eur J Haematol ; 66(1): 31-6, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11168505

ABSTRACT

OBJECTIVES: Recombinant human erythropoietin (rHuEpo) improves anemia in 25% of patients with myelodysplastic syndromes (MDS). The variable and sometimes low response rate to rHuEpo treatment raises the question whether the existence of autoantibodies against erythropoietin (epo) is partially responsible. In the present study we investigated the presence of anti-epo autoantibodies in MDS patients. METHODS: Forty-three patients with MDS were studied. Sixteen patients had refractory anemia (RA), 13 had RA with ringed sideroblasts, 3 had RA with excess of blasts (RAEB), 9 had RAEB in transformation and 2 patients had chronic myelomonocytic leukemia. They were divided in 3 groups according to rHuEpo treatment. Group A consisted of 10 patients who did not receive rHuEpo treatment. Group B included 13 patients who were on rHuEpo treatment (150 IU/kg subcutaneously, 3 times weekly) showing an increase of hemoglobin (Hb) values or reduction of transfusion requirements and Group C consisted of 20 patients who did not respond or stopped responding to rHuEpo treatment. Laboratory studies consisted of a complete blood cell count, measurement of serum epo and determination of anti-epo antibodies using ELISA. RESULTS: There were no significant differences with regard to age and sex among the three groups. No autoantibodies against epo were found in the examined sera, apart from a female patient from group A who showed a low positive titer. CONCLUSION: We suggest that anti-epo autoantibodies do not contribute to the development of MDS-related anemia and are not responsible for the modest response to rHuEpo treatment. Further investigation is needed to identify possible reasons for the low response rate to rHuEpo treatment.


Subject(s)
Autoantibodies/blood , Autoantigens/immunology , Erythropoietin/immunology , Isoantibodies/blood , Isoantigens/immunology , Myelodysplastic Syndromes/immunology , Aged , Aged, 80 and over , Anemia, Refractory/blood , Anemia, Refractory/drug therapy , Anemia, Refractory/immunology , Anemia, Refractory/therapy , Anemia, Refractory, with Excess of Blasts/blood , Anemia, Refractory, with Excess of Blasts/drug therapy , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/therapy , Antibody Specificity , Autoantibodies/immunology , Blood Cell Count , Blood Transfusion , Combined Modality Therapy , Erythropoietin/therapeutic use , Female , Hemoglobins/analysis , Humans , Isoantibodies/immunology , Leukemia, Myelomonocytic, Chronic/blood , Leukemia, Myelomonocytic, Chronic/drug therapy , Leukemia, Myelomonocytic, Chronic/immunology , Leukemia, Myelomonocytic, Chronic/therapy , Male , Middle Aged , Myelodysplastic Syndromes/blood , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/therapy , Recombinant Proteins/immunology , Recombinant Proteins/therapeutic use , Treatment Failure
13.
J Exp Clin Cancer Res ; 18(4): 565-6, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10746986

ABSTRACT

We describe the simultaneous presentation of myelodysplastic syndrome (MDS) and multiple myeloma (MM). Our patient had MDS (RAEB type) and bone marrow infiltration (40% plasma cells), as well as biclonal paraprotein. Patients with MM, MDS have been reported after chemotherapy but few cases documenting the coexistence of MDS and MM at diagnosis have been reported in the literature.


Subject(s)
Anemia, Refractory, with Excess of Blasts/complications , Multiple Myeloma/complications , Aged , Aged, 80 and over , Anemia, Refractory, with Excess of Blasts/diagnosis , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/pathology , Bone Marrow/pathology , Humans , Immunoglobulin A/blood , Immunoglobulin G/blood , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Male , Multiple Myeloma/diagnosis , Multiple Myeloma/immunology , Multiple Myeloma/pathology
14.
Intern Med ; 37(11): 973-7, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9868964

ABSTRACT

Two cases of myelodysplastic syndrome (MDS) with extramedullary polyclonal plasma cell proliferation and autoantibody production are reported. These cases, which showed leukemic change of refractory anemia with excess of blast (RAEB), developed lymph node swelling and muscle abscess; both were infiltrated mainly with plasma cells, without preceding infection. The proliferation of plasma cells was polyclonal and was proven by negative rearrangement of immunoglobulin heavy chain gene or polyclonal staining of immunoglobulin light chains. These patients showed polyclonal gammopathy and autoantibody production such as positive antinuclear factor and direct antiglobulin test. As was observed in one of the present cases, and as we reported previously, the elevated level of soluble Fas antigen in MDS patients, and its inhibition of apoptotic signaling may be responsible for the excessive accumulation of self-reactive B cells, resulting in these clinical manifestations.


Subject(s)
Anemia, Refractory, with Excess of Blasts/pathology , Autoantibodies/biosynthesis , B-Lymphocytes/immunology , Myelodysplastic Syndromes/pathology , Plasma Cells/pathology , fas Receptor/immunology , Aged , Aged, 80 and over , Anemia, Refractory, with Excess of Blasts/complications , Anemia, Refractory, with Excess of Blasts/immunology , Antibodies, Antinuclear/biosynthesis , Antibodies, Antinuclear/immunology , Apoptosis/immunology , Autoantibodies/immunology , Biomarkers, Tumor/blood , Biopsy , Bone Marrow/pathology , Cell Division/immunology , Fatal Outcome , Follow-Up Studies , Humans , Male , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/immunology , Plasma Cells/immunology
15.
Leukemia ; 11(6): 839-45, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9177438

ABSTRACT

Apoptosis of hematopoietic progenitor cells is increased in myelodysplastic syndromes (MDS). We have studied Fas (CD95/Apo-1) antigen expression in 27 MDS patients (RARS 4, RA 3, RAEB 13; RAEB-t 3, CMML 4) and three AML secondary to MDS. We found that the Fas antigen was not expressed on normal bone marrow (BM) CD34+, CD14+, or glycophorin+ cells, and only slightly on CD33+ cells. Patients with MDS had upregulation of Fas expression on total bone marrow nuclear cells (BMMC) (t-test, P = 0.04), CD34+ (P = 0.013), CD33+ (P = 0.04), and glycophorin+ (P = 0.032) BM cells compared to controls. Fas expression did not correlate to the FAB subtype, the Bournemouth score, or to peripheral cytopenias. However, Fas expression intensity on CD34+ cells negatively correlated to the BM blasts number (Spearman, P = 0.01) suggesting that leukemic blasts cells lose Fas antigen expression with progression of myelodysplasia. Using both proliferation assays in liquid cultures and clonogenic progenitor assays in the presence of an agonist anti-Fas MoAb (CH11), we showed that the Fas protein was functional in some patients. Dose-dependent inhibition of DNA synthesis was observed in three out of seven patients studied. CFU-GM and BFU-E colonies suppression in some patients suggested that Fas can induce apoptosis in myeloid and erythroid BM progenitors of MDS patients. The TUNEL technique on BM smears gave a mean of 12.6% +/- 2.5 of bone marrow apoptotic cells in five controls. Patients with MDS had increased bone marrow apoptosis (mean 39% +/- 5.7, t-test, P = 0.012). Four out of 15 (26%) patients studied with a sensitive radiolabeled DNA ladder technique had typical DNA ladders indicative of advanced stages of apoptosis. Massive BM suicide was observed in patients with RA (2/2) and RAEB (8/11), whereas apoptosis rates were normal or low in patients with RAEB-t (3/3) or secondary AMLs (3/3). Moreover, high rates of apoptosis correlated to low Bournemouth score (Spearman, P = 0.01). No statistical correlation could be found between Fas expression and apoptosis rates. Our results confirm the importance of programmed cell death in MDS. The Fas antigen is clearly upregulated on BM cells, but its role in the pathophysiology of apoptosis in myelodysplasia is still unclear, indicating that many factors positively or negatively interfere with the Fas-mediated pathway of apoptosis in vivo and in vitro.


Subject(s)
Antigens, CD/biosynthesis , Apoptosis , Hematopoietic Stem Cells/immunology , Hematopoietic Stem Cells/pathology , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/pathology , fas Receptor/biosynthesis , Adult , Aged , Aged, 80 and over , Anemia, Refractory/classification , Anemia, Refractory/immunology , Anemia, Refractory/pathology , Anemia, Refractory, with Excess of Blasts/classification , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/pathology , Antigens, CD/analysis , Bone Marrow/immunology , Bone Marrow/pathology , Bone Marrow Cells , Cells, Cultured , Colony-Forming Units Assay , DNA/analysis , DNA Fragmentation , Female , Hematopoietic Stem Cells/cytology , Humans , Karyotyping , Leukemia, Myeloid/classification , Leukemia, Myeloid/immunology , Leukemia, Myeloid/pathology , Male , Middle Aged , Reference Values , Sensitivity and Specificity , fas Receptor/analysis
16.
Bone Marrow Transplant ; 19(7): 745-7, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9156254

ABSTRACT

A 36-year-old woman with RAEB-t and severe bone marrow fibrosis undergoing autologous BMT, developed a histologically documented GVHD-like skin rash. Thereafter, autoimmune thyroiditis, autoimmune thrombocytopenic purpura and autoimmune hemolytic anemia and a lupus anti-coagulant (LAC) were diagnosed. The patient is still alive, symptom-free and in first complete remission (CR); however, all of the autoantibodies are still detectable, with the exception being the anti-erythrocyte antibody. The most outstanding feature of the present case is the polymorphism of the autoimmune events, in the absence of a coexisting systemic autoimmune disease. This patient has achieved long-term disease-free survival (DFS) in first CR despite high-risk MDS and the repeated immunosuppressant therapy required because of the complications described above; a GVL reaction somewhat similar to the autoimmune events may have contributed towards maintaining disease control.


Subject(s)
Anemia, Refractory, with Excess of Blasts/therapy , Autoimmune Diseases/etiology , Bone Marrow Transplantation/adverse effects , Adult , Anemia, Refractory, with Excess of Blasts/immunology , Female , Humans , Transplantation, Autologous
17.
Br J Dermatol ; 136(3): 402-5, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9115926

ABSTRACT

Specific cutaneous lesions are a rare occurrence in myelodysplastic syndromes (MDS). The concurrent association of blistering skin lesions similar to those in bullous pemphigoid (BP), even though a rare event, suggests that BP may be a paraneoplastic syndrome. We report an 86-year-old man who had a refractory anaemia with excess bone marrow blasts in transformation, who developed a generalized pruritic blistering eruption. Immunohistopathological tests showed subepidermal blisters with linear deposits of IgG and C3 along the basement membrane zone of the epidermis surrounding a tumoral dermal infiltrate of CD13+ and CD15+ cells. Immunoblotting studies using epidermal extracts revealed circulating IgG antibodies against three protein bands: a 210-215 kDa band, a 180 kDa band which co-migrated with the BP 180 antigen, and a 190 kDa band. The tumour infiltrate may have revealed antigenic determinants which led to the onset of BP. The concept of paraneoplastic pemphigoid remains to be either confirmed or invalidated by further epidemiological studies.


Subject(s)
Anemia, Refractory, with Excess of Blasts/complications , Carrier Proteins , Collagen , Nerve Tissue Proteins , Non-Fibrillar Collagens , Pemphigoid, Bullous/complications , Skin/pathology , Aged , Aged, 80 and over , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/pathology , Antibodies/analysis , Autoantigens/analysis , Blotting, Western , Complement C3/analysis , Cytoskeletal Proteins/immunology , Desmoplakins , Dystonin , Humans , Immunoglobulin G/analysis , Immunoglobulin G/immunology , Male , Pemphigoid, Bullous/immunology , Pemphigoid, Bullous/pathology , Skin/immunology , Collagen Type XVII
18.
Bone Marrow Transplant ; 19(6): 571-6, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9085737

ABSTRACT

We have investigated cytokine mRNA expression in the peripheral blood mononuclear cells of 20 patients who received allogeneic hematopoietic stem cell transplants to assess the cytokine network after transplantation. IL-4 mRNA expression decreased in five of five (100%) patients with > or = grade III (severe) acute GVHD and increased in 10 of 22 (45%) patients without severe GVHD. In contrast, IL-12 mRNA expression increased in two of two (100%) patients with severe GVHD, but increased in only six of 18 (33%) patients without severe GVHD. Furthermore, IL-10 and/or IL-13 mRNA expression increased in 19 of 22 (86%) patients without severe GVHD, but increased in only one of three (33%) patients with severe GVHD. In patients with allogeneic PBSCT who had severe acute GVHD, the cytokine mRNA expression in patients with allogeneic PBSCT, who had no severe GVHD, showed a similar pattern to that in patients with allogeneic BMT. IL-4 mRNA expression increased in three of five (60%) patients and IL-10 and/or IL-13 mRNA expression increased in five of five (100%) patients. In contrast, IL-12 mRNA expression increased in only one of three (33%) patients. Serum IL-4 concentration in allogeneic PBSCT patients in the early engraftment phase was relatively high, while serum IL-12 concentration was low. These findings suggest that severe GVHD may be related to the cytokine imbalance between type 1 helper T (Th1) cells and type 2 helper T (Th2) cells.


Subject(s)
Cytokines/biosynthesis , Graft vs Host Disease/immunology , Hematopoietic Stem Cell Transplantation , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Helper-Inducer/immunology , Adult , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/therapy , Female , Gene Expression , Hematologic Neoplasms/immunology , Hematologic Neoplasms/therapy , Humans , Male , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/therapy , RNA, Messenger/biosynthesis , Transplantation, Homologous
20.
Bone Marrow Transplant ; 17(5): 745-51, 1996 May.
Article in English | MEDLINE | ID: mdl-8733692

ABSTRACT

Between December 1981 and March 1994, 24 patients with a myelodysplastic syndrome (MDS) underwent allogeneic bone marrow transplantation (BMT) for RA with trilineage dysplasia (n = 4), CMML (n = 1), RAEB (n = 4), RAEBt (n = 9) and AML following MDS (n = 6). Fifteen patients (two RAEB, seven RAEBt and six sAML) received chemotherapy before BMT resulting in complete remission in 10 patients (six RAEBt and four sAML) at the time of BMT. Sixteen marrow donors were genotypically HLA-identical siblings. Remaining donors were other family members (five) or unrelated donors (three). The status of the underlying disease at the time of conditioning was the major factor determining long-term survival. The disease-freed survival of RA patients and patients presenting with RAEB, RAEBt and AML but transplanted in complete remission, was respectively 50 and 60%. On the contrary, none of the nine high-risk MDS patients transplanted with persistent disease, survived. Outcome after transplantation with alternative donors was inferior with one long-term survivor, mainly related to the high incidence of severe acute GVHD and its accompanying infectious complications. Six patients relapsed resulting in an actuarial probability of relapse of 28%. Twelve patients died of transplant-related complications leading to a non-relapse mortality at 5 years of 50%. At present eight patients are alive and disease-free 20 to 132 months post-transplantation resulting in an actuarial 5-year disease-free survival of 40.7%. Our results suggest that allogeneic bone marrow transplantation is a feasible treatment option for patients with MDS. However, improvement in GVHD prophylaxis and supportive care to reduce transplant-treated mortality and improved relapse prevention are imperative.


Subject(s)
Bone Marrow Transplantation , Myelodysplastic Syndromes/therapy , Adolescent , Adult , Anemia, Refractory, with Excess of Blasts/immunology , Anemia, Refractory, with Excess of Blasts/therapy , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/immunology , Bone Marrow Transplantation/methods , Child, Preschool , Family , Female , Genotype , Graft vs Host Disease/etiology , Graft vs Host Disease/prevention & control , HLA Antigens/genetics , Humans , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/therapy , Living Donors , Lymphocyte Depletion , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Recurrence , T-Lymphocytes/immunology , Transplantation Conditioning , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...